

| type of report      | Current report      |
|---------------------|---------------------|
| number              | 17/2012             |
| date of publication | 2012-04-16 15:32:23 |
| company             | PHARMENA            |

### March 2012 monthly report

The Management Board of Pharmena S.A. hereby presents its monthly report for March 2012:

#### 1. Information on trends and events occurring in the Issuer's market environment

To the best knowledge of the Management Board, in March 2012 no trends or events occurred in the Issuer's market environment which could significantly influence financial results of the company.

In March 2012, Pharmena S.A. developed its network of sales and carried out marketing actions in order to increase sales profit from its marketed products.

In March 2012, the Company continued its research and development work on new products and searched for new applications for active substances protected by patents and patent applications owned by the Company.

On 16<sup>th</sup> March 2012, CORTRIA CORPORATION, a subsidiary company of PHARMENA S.A. received notification that US Patent Office made a decision on granting patent to application no. 12/690,797. The patent will provide protection for the use of 1-methylnicotinamide (1-MNA) in combination with statins in the treatment of lipid profile disorders (by lowering the levels of triglycerides and increasing the level of the so-called "good" cholesterol HDL) on the US market. This patent is of great importance to the process of commercialisation of the 1-MNA project, due to the fact that American market constitutes ca. 45% of the world market value of dyslipidemia, which was estimated at 42 billion USD in 2012. Dyslipidemia is a disease characterized by lipid profile disorders. Potentially, 1-MNA in combination with statins may provide complete treatment, through correction of all lipid profile parameters.

On 28<sup>th</sup> March 2012, the Supervisory Board granted positive opinion on the Management Board's motion, which suggested the following division of 2011 profit:

- a) for dividend – the amount of 312,713 PLN (say: three hundred twelve thousand seven hundred and thirteen PLN 00/100), i.e. 0.05 PLN per share,
- b) for supplementary capital – the amount of 296,284.21 PLN (say: two hundred ninety-six thousand two hundred eighty-four PLN 21/100).

This proposal for division of 2011 profit will be one of the items of the agenda of Ordinary General Meeting of Shareholders, taking place on 14<sup>th</sup> May 2012 (which the Company informed about in its current report no. 14/2012 of 13<sup>th</sup> April 2012).

On 30<sup>th</sup> March 2012, the Management Board of Pharmena S.A. informed about the commencement of cooperation in Poland with Rossmann – one of most prominent health and beauty retail chain stores in Europe. In Poland Rossmann is the industry leader with a chain of self-service outlets all over the country. Currently, the network features over 600 stores localized in 270 cities and towns in Poland. The products of Pharmena S.A. will be available in dermatological sections of Rossmann stores.

It is estimated that the cooperation with Rossmann will, over the next few years, significantly contribute to the increase of the Company's revenue, due to dynamic growth of Rossmann in Poland. Commencing cooperation with Rossmann complies with the Company's strategy focused on the expansion of distribution channels by entering the segment of health and beauty retail chain stores. This step will enable reaching new customers, because until this moment, the Company sold its products via pharmacies.

In March 2012, the Company undertook actions headed for commercialisation of studies on innovative anti-atherosclerosis medicinal product (1-MNA) in cooperation with Torrey Partners. The studies on the medicinal product are carried out in USA and Canada by a subsidiary company Cortria Corporation.

#### 2. Achievement of the goals of an issue

In March 2012, Pharmena S.A. did not make any money expenditure directly on issue-related purposes. However, a subsidiary company Cortria Corporation spent its funds on research on animal models, which had been carried out in 2011.

#### 3. A list of all information published by the Issuer in the form of current reports in the reporting period from 1<sup>st</sup> March 2012 to 31<sup>st</sup> March 2012

During the period covered by this report, Pharmena S.A. published the following reports in EBI system:

Current report no. 8/2012 of 14<sup>th</sup> March 2012 – February 2012 monthly report

Current report no. 9/2012 of 16<sup>th</sup> March 2012 - Obtaining a patent in USA

Current report no. 10/2012 of 26-03-2012 - Change in date of publication of the 2011 annual report

Current report no. 11/2012 of 28-03-2012 - Proposition on payment of dividend for 2011

Current report no. 12/2012 of 30-03-2012 - Commencing cooperation with Rossmann – health and beauty retail chain stores

During the period covered by this report, Pharmena S.A. did not publish any reports in ESPI system.

4. Investor's calendar April 2012

Publication of April 2012 monthly report until 14<sup>th</sup> May 2012.

Legal basis: Resolution No. 795/2008 of the Warsaw Stock Exchange Management Board dated 31<sup>st</sup> November 2008 concerning the adoption of the codes of best practice applicable on the NewConnect market, Appendix 1, point 16.

**Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board